A CDC advisory committee will meet June 27 to vote on recommendations for the vaccine. The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the ...

The FDA's approval is partly based on Merck's late-stage trial called STRIDE-3 that pitted the vaccine against Pfizer's Prevnar 20 in adults 18 and up who had not previously received a ...

The Food and Drug Administration (FDA) has approved pharmaceutical company Merck’s (NYSE:MRK) new vaccine, Capvaxive. This pneumococcal conjugate vaccine is designed to prevent invasive disease ...

FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease Provided by Dow Jones Jun 17, 2024, 10:05:00 PM. By Emon Reiser . The Food and Drug Administration approved Merck's Capvaxive ...

Merck (MRK) has received FDA approval for its Capvaxive 21-valent conjugate vaccine for the prevention of pneumonia in adults aged 50 or older. Read more here.

Merck (MRK) stock is higher after its vaccine for pneumococcal disease received Food and Drug Administration (FDA) approval BREAKING NEWS: S&P 500, Nasdaq Snap Win Streaks Amid Tesla Turmoil ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia ...

Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, ... US FDA approves Merck's pneumococcal vaccine for adults. June 17, 2024 at 5:52 PM.